Trisenox® (arsenic trioxide) is indicated for induction of remission and consolidation in adult patients with relapsed/refractory acute promyelocytic leukaemia (APL), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptoralpha (PML/RAR-alpha) gene. Previous treatment should have included a retinoid and chemotherapy.1
The response rate of other acute myelogenous leukaemia subtypes to Trisenox® has not been examined.1
1mL of Trisenox® contains 1mg of arsenic trioxide
For a full list of excipients, see Section 6.1 of the Summary of Product Characteristics.1
2031 GA Haarlem
Marketing Authorisation Number(s)
1 Trisenox® (arsenic trioxide) Summary of Product Characteristics.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.